Ignite Creation Date:
2024-05-06 @ 2:00 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01944371
Status:
COMPLETED
Last Update Posted:
2020-05-05
First Post:
2013-09-12
Brief Title:
Short-term Disulfiram Administration to Reverse Latent HIV Infection a Dose Escalation Study
Sponsor:
University of California San Francisco
Organization:
University of California San Francisco
Study Overview
Official Title:
Short-term Disulfiram Administration to Reverse Latent HIV Infection a Dose Escalation Study
Status:
COMPLETED
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults The investigators primary hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in CD4 T-cells in patients on suppressive antiretroviral therapy ART
Detailed Description:
Combination antiretroviral therapy for HIV-1 infection can suppress viremia to below the detection limit in the vast majority of motivated individuals with access to these drugs However HIV-1 persists in a small pool of latently infected resting memory CD4 T cells carrying integrated viral genomes Although other reservoirs for HIV-1 exist the general consensus among experts is that latent virus HIV DNA in resting memory CD4 T cells is the primary barrier to HIV-1 eradication A widely discussed approach for eliminating this viral reservoir requires reactivation of latent HIV-1 Disulfiram an FDA-approved drug used to treat alcoholism was shown to activate HIV-1 gene expression in vitro suggesting that activation of latently infected cells in vivo may occur Our primary hypothesis is that the addition of disulfiram to a stable effective antiretroviral drug regimen will result in a dose dependent increase in HIV transcription in CD4 T-cells in HIV-1 in patients on highly active antiretroviral therapy HAART
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DAIDS-ES ID 11864 | OTHER_GRANT | None | None |
| K24AI069994 | NIH | NIAID | httpsreporternihgovquickSearchK24AI069994 |